Table 2.
JADAS-10; median (IQR)a | Month 0 | Month 3 | Month 6 | Month 12 | Month 18 | Month 24 | Last observation |
ETA | 20.8 (14; 28.4) | 6.9 (2.5; 14.3) | 6.2 (1.1; 14.7) | 3.8 (0.7; 15.7) | 4.1 (1.5; 15.2) | 3.3 (0.7; 9.4) | 9.1 (2.1; 19.1) |
TOC | 16.9 (8.1; 24.8) | 3.6 (0.8; 10.7) | 1.5 (0.2; 3.8) | 1.6 (0.4; 6.7) | 0.9 (0.2; 2.0) | 0.9 (0.1; 7.5) | 0.9 (0.1; 4) |
IL-1i | 13 (6.7; 20.6) | 0.8 (0.2; 1.6) | 0.6 (0.2; 2.1) | 0.8(0.2; 2.6) | 0.2 (0; 1.9) | 0.2 (0.1; 0.8) | 0.8 (0.1; 5.1) |
Patients with active systemic signs; n (%)b | |||||||
ETA | 2 (1%) | 0 | 0 | 2 (2.5%) | 0 | 0 | 1 (1%) |
TOC | 30 (42%) | 5 (14%) | 3 (6%) | 3 (7%) | 2 (5%) | 1 (4%) | 4 (7%) |
IL-1i | 40 (63%) | 9 (32%) | 8 (22%) | 8 (21%) | 8 (26%) | 4 (17%) | 6 (11%) |
Active joints; median (IQR)a | |||||||
ETA | 4 (2; 11) | 1 (0; 3) | 1 (0; 5) | 0 (0; 4) | 0.5 (0; 4) | 0.5 (0; 4) | 1 (0; 6) |
TOC | 3.0 (0; 6) | 0 (0; 0.5) | 0 (0; 0.3) | 0 (0; 1.0) | 0 (0; 0) | 0 (0; 1.0) | 0 (0; 0) |
IL-1i | 2 (0; 5) | 0 (0; 0.3) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) |
Patients with active joints; n (%)b | |||||||
ETA | 121 (85%) | 48 (53%) | 49 (52%) | 39 (48%) | 36 (50%) | 36 (50%) | 67 (53%) |
TOC | 49 (69%) | 9 (26%) | 12 (25%) | 13 (29%) | 7 (19%) | 8 (29%) | 15 (21%) |
IL-1i | 34 (60%) | 7 (25%) | 6 (17%) | 8 (21%) | 7 (23%) | 2 (9%) | 12 (21%) |
Patients on steroid use; n (%)b | |||||||
ETA | 119 (83%) | 66 (72%) | 73 (76%) | 48 (59%) | 36 (49%) | 35 (56%) | 65 (49%) |
TOC | 32 (44%) | 13 (35%) | 16 (31%) | 7 (14%) | 6 (15%) | 8 (27%) | 7 (11%) |
IL-1i | 27 (45%) | 12 (48%) | 15 (45%) | 10 (29%) | 7 (25%) | 6 (27%) | 12 (24%) |
Data as observed
JADAS Juvenile Disease Activity Score, ETA etanercept, TOC tocilizumab, IL-li interleukin-1 inhibitor
aData are given as median and interquartile range of patients on treatment as observed. Note, the median value was higher in the last observation on ETA than on TOC or IL-1i
bPercentage of patients reported